Hyrimoz(Cf) Pen Psoriasis (Adalimumab-Adaz) Patent Expiration, LOE Window & CMS Spending
Hyrimoz(Cf) Pen Psoriasis (Adalimumab-Adaz) by Sandoz: Off-Patent Genericized (AB Competition), 0 AB generics, $481K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sandoz |
| FDA Application & Pathway | Reconciled (UNLINKED) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $481K |
| 2024 Medicare Part D Spend | $283K |
| 2024 Medicaid Spend | $198K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |